Announcements Trials
Browse Landscape

Phase

Phase 2 18Phase 3 9Phase 1 6Phase 1/2 5Phase EARLY_PHASE1 2

Status

Withdrawn 1Terminated 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Breast 2

Conditions

Breast Neoplasms 4Triple Negative Breast Neoplasms 2Glioblastoma 2Carcinoma, Non-Small-Cell Lung 2Sarcoma 1Prostatic Neoplasms 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Carcinoma, Transitional Cell 1Carcinoma, Hepatocellular 1Adenoviridae Infections 1

Interventions

pembrolizumab 3atezolizumab 2trametinib 1sargramostim 1ruxolitinib 1reolysin 1poly(I).poly(c12,U) 1poly ICLC 1neratinib 1incomplete Freund's adjuvant 1glembatumumab vedotin 1epigallocatechin gallate 1entinostat 1dupilumab 1Zymosan 1Zinc 1Watchful Waiting 1Vaccines 1Uridine Monophosphate 1Trastuzumab 1Technetium Tc 99m Sestamibi 1Taxes 1Quercetin 1Positron-Emission Tomography 1Paclitaxel 1Neurofibromin 2 1Neoadjuvant Therapy 1Metformin 1Leukapheresis 1Letrozole 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase EARLY_PHASE1 × Triple Negative Breast Neoplasms × atezolizumab × Clear all
NCT04249167 2023-01-06

Cryoablation, Atezolizumab/Nab-paclitaxel for Locally Advanced or Metastatic Triple Negative Breast Cancer

Mayo Clinic

Phase EARLY_PHASE1 Withdrawn
Breast

Triple Negative Breast Neoplasms

NCT04102618 2022-08-15

AWARE-1

Oncolytics Biotech

Phase EARLY_PHASE1 Terminated
26 enrolled
Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡